Aetna modified CPB 0712 covering ziconotide (Prialt) intrathecal infusion, effective November 27, 2025. Here's what billing teams need to act on now.
Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0712 to clarify medical necessity criteria and exclusions for ziconotide (Prialt) intrathecal administration. The primary reimbursement code is HCPCS J2278 (injection, ziconotide, 1 mcg), with related procedures billed under CPT codes 62320–62327 and 62350–62362. This Aetna ziconotide coverage policy draws a hard line between covered chronic pain treatment and a growing list of experimental indications — and the exclusions carry real denial risk if your documentation doesn't match the criteria exactly.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Ziconotide (Prialt) — CPB 0712 |
| Policy Code | CPB 0712 |
| Change Type | Modified |
| Effective Date | November 27, 2025 |
| Impact Level | High |
| Specialties Affected | Pain Management, Neurology, Oncology, Anesthesiology, Interventional Spine |
| Key Action | Confirm all ziconotide claims include documentation of intolerance or refractoriness to prior treatments before billing J2278 |
Aetna Ziconotide Coverage Criteria and Medical Necessity Requirements 2025
The Aetna ziconotide coverage policy under CPB 0712 is narrow by design. Aetna covers intrathecal (IT) administration of ziconotide when a member has severe chronic pain and is intolerant of or refractory to treatments such as:
| # | Covered Indication |
|---|---|
| 1 | Systemic analgesics |
| 2 | Adjunctive therapies |
| 3 | IT morphine |
The policy uses "or" — not "and." Aetna requires that the member be intolerant of or refractory to treatments such as these, not that every category be separately exhausted. Document which treatment the patient failed or couldn't tolerate, and why.
Medical necessity requires that documentation clearly establish treatment intolerance or refractoriness. "Intolerant of" and "refractory to" are two distinct paths — document which one applies and why.
Absolute Contraindications That Trigger Non-Coverage
Aetna explicitly calls out three IT-specific contraindications and one psychiatric contraindication that make ziconotide not medically necessary:
| # | Covered Indication |
|---|---|
| 1 | Pre-existing history of psychosis — ICD-10 codes F23, F24, F28, F29, and Z86.59 are all listed. If any of these appear in the member's history, the claim won't fly. |
| 2 | Infection at the microinfusion injection site |
| 3 | Uncontrolled bleeding diathesis — mapped to D69.9 |
| 4 | Spinal canal obstruction — mapped to C72.0, D33.4, M48.0–M48.8 |
These aren't soft exclusions. Aetna treats them as hard stops. If any of these diagnosis codes appear in the patient's record, don't submit the claim without a compliance review first.
Aetna Ziconotide Exclusions and Non-Covered Indications
This is where the CPB 0712 update gets important for billing teams. Aetna now explicitly lists six conditions where ziconotide is experimental, investigational, or unproven — regardless of route of administration:
| # | Excluded Procedure |
|---|---|
| 1 | Autism (ICD-10: F84.0) |
| 2 | Epilepsy (ICD-10: G40.001–G40.B19) |
| 3 | Irukandji syndrome (ICD-10: T63.621A–T63.624S — toxic effect of jellyfish contact) |
| 4 | Migraines (ICD-10: G43.001–G43.919) |
| 5 | Primary lateral sclerosis (ICD-10: G12.23) |
| 6 | Stroke (ICD-10: I63.0–I63.9, I65.01–I66.9, I67.0–I68.8, G45.0–G45.9, G46.0–G46.2) |
The stroke exclusion is broad. It covers cerebral infarction, TIA, occlusion and stenosis of precerebral and cerebral arteries, and other cerebrovascular diseases. If your pain management team is treating post-stroke neuropathic pain with ziconotide, that's an experimental designation under this coverage policy. Document your appeal strategy before you bill.
There's also a specific combination therapy exclusion: the intrathecal triple combination of ziconotide + morphine + levobupivacaine is not covered for cancer-related refractory pain. This is a narrow exclusion — it applies to that specific three-drug intrathecal combination, not to billing J2278 alongside morphine codes in other clinical contexts. If your oncology pain patients are on this exact regimen, talk to your compliance officer before you bill.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Severe chronic pain — refractory to or intolerant of treatments such as systemic analgesics, adjunctive therapies, or IT morphine | Covered | J2278, G89.0–G89.4, CPT 62320–62327, 62350–62362 | Document which treatment the patient failed or couldn't tolerate, and why |
| Pre-existing history of psychosis | Not Covered | F23, F24, F28, F29, Z86.59 | Hard contraindication — absolute denial |
| Infection at microinfusion injection site | Not Covered | — | IT analgesia contraindication |
| Uncontrolled bleeding diathesis | Not Covered | D69.9 | IT analgesia contraindication |
| Spinal canal obstruction | Not Covered | C72.0, D33.4, M48.0–M48.8 | IT analgesia contraindication |
| Autism | Experimental / Not Covered | F84.0 | Any route of administration |
| Epilepsy | Experimental / Not Covered | G40.001–G40.B19 | Any route of administration |
| Irukandji syndrome | Experimental / Not Covered | T63.621A–T63.624S | Any route of administration |
| Migraines | Experimental / Not Covered | G43.001–G43.919 | Any route of administration |
| Primary lateral sclerosis | Experimental / Not Covered | G12.23 | Any route of administration |
| Stroke / cerebrovascular disease | Experimental / Not Covered | I63.0–I63.9, I65.01–I66.9, I67.0–I68.8, G45.0–G46.2 | Broad exclusion covering TIA, infarction, and related syndromes |
| IT combination: ziconotide + morphine + levobupivacaine for cancer pain | Experimental / Not Covered | J2278, J2270, J2272 | Specific triple-drug intrathecal combination — cancer-related refractory pain only |
| Cancer-related pain (ziconotide alone, criteria met) | Covered | C00.0–D09.9, J2278 | Must still meet all standard medical necessity criteria |
Aetna Ziconotide Billing Guidelines and Action Items 2025
The billing guidelines for ziconotide under CPB 0712 require documentation rigor that most practices underestimate. Here's what to do before the November 27, 2025 effective date:
| # | Action Item |
|---|---|
| 1 | Audit your active ziconotide patients for contraindication codes. Pull any patient with ICD-10 codes F23, F24, F28, F29, Z86.59, D69.9, C72.0, D33.4, or M48.0–M48.8 in their record. These patients face automatic non-coverage. Flag them now before a claim goes out. |
| 2 | Update your documentation to reflect the policy's "or" structure. Your clinical notes need to show that the patient is intolerant of or refractory to treatments such as systemic analgesics, adjunctive therapies, or IT morphine. Document which treatment failed or wasn't tolerated, and why. |
| 3 | Separate "refractory to" from "intolerant of" in your clinical notes. These are distinct pathways in the policy. Refractory means the treatment didn't work. Intolerant means the patient couldn't tolerate it due to side effects or other factors. The distinction matters when Aetna reviews your medical records. |
| 4 | Don't bill the triple intrathecal combination for cancer pain without a compliance review. The experimental designation applies to the specific combination of ziconotide, morphine, and levobupivacaine given intrathecally for cancer-related refractory pain. It doesn't broadly prohibit ziconotide alongside morphine codes in other contexts. If your oncology pain patients are on this exact regimen, talk to your compliance officer before the claim goes out. |
| 5 | Verify implantable pump codes are included in your claim submissions. CPT 62360, 62361, and 62362 all cover implantation or replacement of devices for intrathecal or epidural drug infusion. HCPCS E0783 covers implantable programmable infusion pump systems. These are high-dollar items — confirm your claim includes all relevant codes for the work performed. |
| 6 | Review your ICD-10 coding for pain diagnoses. The covered pain codes under this policy are G89.0–G89.4. These codes distinguish various pain classifications. Make sure your coders aren't defaulting to unspecified pain codes when a more specific G89 code applies — specificity helps your medical necessity argument. |
| 7 | Don't bill ziconotide for stroke patients under any circumstances without a denial strategy in place. The stroke exclusion covers ICD-10 ranges I63.0–I63.9, I65.01–I66.9, I67.0–I68.8, G45.0–G46.2. That's a wide net. Post-stroke pain is a real clinical problem, but Aetna has classified ziconotide as experimental for it. If you believe a patient has a compelling case, document it for appeal before you bill — not after. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Ziconotide Under CPB 0712
HCPCS Codes — Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J2278 | HCPCS | Injection, ziconotide, 1 mcg |
CPT and HCPCS Codes — Related to the Policy (Not Independently Covered)
These codes support ziconotide billing — catheter placement, pump implantation, and home infusion. Include them in your charge capture as appropriate.
| Code | Type | Description |
|---|---|---|
| 62320 | CPT | Injection(s) of diagnostic or therapeutic substance(s) (e.g., anesthetic, antispasmodic, opioid, steroid) — cervical or thoracic, without imaging guidance |
| 62321 | CPT | Injection(s) of diagnostic or therapeutic substance(s) — cervical or thoracic, with imaging guidance |
| 62322 | CPT | Injection(s) of diagnostic or therapeutic substance(s) — lumbar or sacral, without imaging guidance |
| 62323 | CPT | Injection(s) of diagnostic or therapeutic substance(s) — lumbar or sacral, with imaging guidance |
| 62324 | CPT | Injection(s) including indwelling catheter placement, continuous infusion or intermittent bolus — cervical or thoracic, without imaging guidance |
| 62325 | CPT | Injection(s) including indwelling catheter placement, continuous infusion or intermittent bolus — cervical or thoracic, with imaging guidance |
| 62326 | CPT | Injection(s) including indwelling catheter placement, continuous infusion or intermittent bolus — lumbar or sacral, without imaging guidance |
| 62327 | CPT | Injection(s) including indwelling catheter placement, continuous infusion or intermittent bolus — lumbar or sacral, with imaging guidance |
| 62350 | CPT | Implantation, revision, or repositioning of tunneled intrathecal or epidural catheter for long-term administration |
| 62351 | CPT | Implantation, revision, or repositioning of tunneled intrathecal or epidural catheter for long-term administration, with laminectomy |
| 62360 | CPT | Implantation or replacement of device for intrathecal or epidural drug infusion |
| 62361 | CPT | Implantation or replacement of device for intrathecal or epidural drug infusion |
| 62362 | CPT | Implantation or replacement of device for intrathecal or epidural drug infusion |
| 99601 | CPT | Home infusion/specialty drug administration — per visit, up to 2 hours |
| 99602 | CPT | Home infusion/specialty drug administration — each additional hour |
| E0779 | HCPCS | Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater |
| E0780 | HCPCS | Ambulatory infusion pump, mechanical, reusable, for infusion less than 8 hours |
| E0781 | HCPCS | Ambulatory infusion pump, single or multiple channels, electric or battery operated |
| E0783 | HCPCS | Infusion pump system, implantable, programmable (includes all components) |
| E0785 | HCPCS | Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement |
| E0786 | HCPCS | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) |
| J2270 | HCPCS | Injection, morphine sulfate, up to 10 mg |
| J2272 | HCPCS | Injection, morphine sulfate (Fresenius Kabi), not therapeutically equivalent to J2270, up to 10 mg |
| S0093 | HCPCS | Injection, morphine sulfate, 500 mg (loading dose for infusion pump) |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Coverage Context |
|---|---|---|
| G89.0–G89.4 | Pain, not elsewhere classified [severe chronic pain that is intolerant of or refractory to other treatments] | Covered — severe chronic pain |
| C00.0–D09.9 | Malignant neoplasms and carcinoma in situ | Covered — cancer-related pain (ziconotide alone) |
| F23 | Brief psychotic disorder | Contraindication — not covered |
| F24 | Shared psychotic disorder | Contraindication — not covered |
| F28 | Other psychotic disorder | Contraindication — not covered |
| F29 | Unspecified psychosis | Contraindication — not covered |
| Z86.59 | Personal history of other mental and behavioral disorders (psychosis) | Contraindication — not covered |
| D69.9 | Hemorrhagic condition, unspecified | Contraindication — uncontrolled bleeding diathesis |
| C72.0 | Malignant neoplasm of spinal cord | Contraindication — spinal canal obstruction |
| D33.4 | Benign neoplasm of spinal cord | Contraindication — spinal canal obstruction |
| M48.0–M48.8 | Spinal stenosis | Contraindication — spinal canal obstruction |
| F84.0 | Autistic disorder | Experimental — not covered |
| G12.23 | Primary lateral sclerosis | Experimental — not covered |
| G40.001–G40.B19 | Epilepsy and recurrent seizures | Experimental — not covered |
| G43.001–G43.919 | Migraine | Experimental — not covered |
| G45.0–G45.9 | Transient cerebral ischemic attack and related syndromes | Experimental — not covered (stroke exclusion) |
| G46.0–G46.2 | Cerebral artery syndromes | Experimental — not covered (stroke exclusion) |
| I63.0–I63.9 | Cerebral infarction | Experimental — not covered |
| I65.01–I66.9 | Occlusion and stenosis of precerebral and cerebral arteries | Experimental — not covered |
| I67.0–I68.8 | Other cerebrovascular diseases | Experimental — not covered |
| T63.621A–T63.624S | Toxic effect of contact with other jellyfish (Irukandji syndrome) | Experimental — not covered |
Get the Full Picture for CPT 62320
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.